Condition (MeSH)
Cutaneous Malignant Melanoma
ClinicalTrials.gov lists 5 trials for Cutaneous Malignant Melanoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 5 trials are tagged with Cutaneous Malignant Melanoma itself; the rest are tagged with a narrower condition beneath it.
When did Cutaneous Malignant Melanoma trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 3
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2021 | 1 |
| 2015 | 1 |
| 2012 | 1 |
| 2011 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 5 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cutaneous Malignant Melanoma trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 1 |
How many Cutaneous Malignant Melanoma trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which serious adverse events do Cutaneous Malignant Melanoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Surgical and medical procedures | 12 | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 11 | 1 |
| Gastrointestinal disorders | 8 | 1 |
| Musculoskeletal and connective tissue disorders | 8 | 1 |
| Cardiac disorders | 6 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Cutaneous Malignant Melanoma? (104)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden. | The Lancet. Oncology | 2025 | Yes |
| The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. | Swiss medical weekly | 2025 | No |
| Comparative analysis of ALA mediated sonodynamic therapy considering tumor size, light combination and ultrasound delivery in murine cutaneous melanoma. | Scientific reports | 2025 | No |
| Neoadjuvant treatment for stage III and IV cutaneous melanoma. | The Cochrane database of systematic reviews | 2023 | No |
| Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery. | European journal of cancer (Oxford, England : 1990) | 2023 | No |
Showing 5 of 104 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, prevalence, and rare-disease identity.
Not computed for conditions with fewer than 10 trials: drugs tested.